Protalix BioTherapeutics, Inc. — Investor Relations & Filings
Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| OWNERSHIP DOCUMENT | 2022-02-28 | English | |
| OWNERSHIP DOCUMENT | 2022-02-28 | English | |
| 8-K | 2022-02-24 | English | |
| PROTALIX BIOTHERAPEUTICS, INC. | 2022-02-14 | English | |
| PROTALIX BIOTHERAPEUTICS, INC. | 2022-02-11 | English | |
| SC 13G/A | 2022-01-31 | English |
Browse filings by year
31 years- 2026 7 filings
- 2025 39 filings
- 2024 22 filings
- 2023 41 filings
- 2022 47 filings
- 2021 39 filings
- 2020 55 filings
- 2019 49 filings
- 2018 46 filings
- 2017 43 filings
- 2016 33 filings
- 2015 48 filings
- 2014 35 filings
- 2013 27 filings
- 2012 46 filings
- 2011 37 filings
- 2010 50 filings
- 2009 70 filings
- 2008 43 filings
- 2007 91 filings
- 2006 10 filings
- 2005 12 filings
- 2004 7 filings
- 2003 4 filings
- 2002 5 filings
- 2001 6 filings
- 2000 5 filings
- 1999 11 filings
- 1998 10 filings
- 1997 10 filings
- 1996 2 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2022
6 filings
| |||||
| 10685333 | OWNERSHIP DOCUMENT | 2022-02-28 | English | ||
| 10685340 | OWNERSHIP DOCUMENT | 2022-02-28 | English | ||
| 10685339 | 8-K | 2022-02-24 | English | ||
| 10685335 | PROTALIX BIOTHERAPEUTICS, INC. | 2022-02-14 | English | ||
| 10685337 | PROTALIX BIOTHERAPEUTICS, INC. | 2022-02-11 | English | ||
| 10685336 | SC 13G/A | 2022-01-31 | English | ||
|
2021
9 filings
| |||||
| 10685346 | 8-K | 2021-12-22 | English | ||
| 10685343 | 8-K | 2021-11-24 | English | ||
| 10685351 | 10-Q | 2021-11-15 | English | ||
| 10685354 | 8-K | 2021-11-15 | English | ||
| 10685356 | DEFA14A | 2021-11-09 | English | ||
| 10685360 | 8-K | 2021-10-12 | English | ||
| 10685361 | DEF 14A | 2021-09-30 | English | ||
| 10685362 | PRE 14A | 2021-09-17 | English | ||
| 10685364 | 8-K | 2021-08-26 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Protalix BioTherapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33807/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33807 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33807 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33807 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33807}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Protalix BioTherapeutics, Inc. (id: 33807)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.